We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-5.98%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$106M
AUM Growth
-$10.8M
Cap. Flow
+$475K
Cap. Flow %
0.45%
Top 10 Hldgs %
66.88%
Holding
54
New
8
Increased
10
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
ARCT icon
Arcturus Therapeutics
ARCT
+$1.3M
2
RIOT icon
Riot Platforms
RIOT
+$1.25M
3
ECI
ENCISION INC
ECI
+$1.13M
4
OCRX
Ocera Therapeutics, Inc.
OCRX
+$776K
5
FATE icon
Fate Therapeutics
FATE
+$535K

Top Sells

Rank Stock Value
1
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$2.6M
2
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$1.53M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$873K
4
DMK
DMK Pharmaceuticals Corporation Common Stock
DMK
+$795K
5
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
+$691K

Sector Composition

Rank Sector Weight
1 Healthcare 69.94%
2 Financials 1.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTR
26
DELISTED
CytRx Corp
CYTR
$941K 0.89%
37,500
– –
ELOS
27
DELISTED
Syneron Medical Ltd
ELOS
$939K 0.89%
90,947
– –
CUTR
28
DELISTED
Cutera, Inc.
CUTR
$922K 0.87%
88,694
– –
EXAC
29
DELISTED
Exactech Inc
EXAC
$798K 0.76%
31,636
– –
SRGA
30
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$727K 0.69%
5,569
– –
FATE icon
31
Fate Therapeutics
FATE
$283M
$479K 0.45%
+75,930
New +$535K
ICPT
32
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$473K 0.45%
2,000
– –
APEN
33
DELISTED
Apollo Endosurgery, Inc.
APEN
$417K 0.4%
1,364
– –
MASI
34
DELISTED
Masimo
MASI
$413K 0.39%
17,500
– –
SCYX icon
35
SCYNEXIS
SCYX
$35.5M
$401K 0.38%
+625
New +$438K
ARDX icon
36
Ardelyx
ARDX
$1.25B
$399K 0.38%
+25,000
New +$383K
TNXP icon
37
Tonix Pharmaceuticals
TNXP
$165M
– –
0
– –
CRIS icon
38
Curis
CRIS
$9.14M
$279K 0.26%
75
– –
AKTX
39
Akari Therapeutics
AKTX
$14.8M
$272K 0.26%
5
– –
BLFS icon
40
BioLife Solutions
BLFS
$1.46B
$265K 0.25%
+116,279
New +$314K
GNVC
41
DELISTED
GenVec, Inc.
GNVC
$257K 0.24%
10,000
– –
NSPR icon
42
InspireMD
NSPR
$32.3M
– –
0
– –
TBRA
43
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$204K 0.19%
+3,333
New +$203K
CEMI
44
DELISTED
Chembio diagnostics, Inc.
CEMI
$189K 0.18%
55,202
– –
LMNS
45
DELISTED
LUMENIS LTD CL B ORD SHS (ISR)
LMNS
$92K 0.09%
+9,478
New +$88K
NWBO
46
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$81K 0.08%
+12,017
New +$76.5K
RVP icon
47
Retractable Technologies
RVP
$20.1M
$50K 0.05%
20,000
– –
DMK
48
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-1,786
Closed -$795K
CLVS
49
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-12,600
Closed -$873K
AVEO
50
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-26,151
Closed -$391K
1
2
3

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, DAFNA Capital Management held 54 positions worth $106M, down 9.3% from $116M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

DAFNA Capital Management's Q2 2014 filing shows 8 new, 10 increased, 2 reduced and 5 closed positions. Its largest new stake was ENCISION INC: 1,062,500 shares worth $1.13M. The largest sale was Merrimack Pharmaceuticals, Inc., an estimated $2.6M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 71% a quarter earlier, followed by Financials.

  • DAFNA Capital Management's largest Q2 2014 buy was ENCISION INC: 1,062,500 shares worth $1.13M.
  • DAFNA Capital Management added most to Arcturus Therapeutics in Q2 2014, an estimated $1.3M increase.
  • DAFNA Capital Management's biggest Q2 2014 reduction was Ampio Pharmaceuticals Inc., cutting an estimated $1.53M.
  • DAFNA Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2014, selling an estimated $2.6M.
  • DAFNA Capital Management's ten largest holdings make up 67% of its $106M portfolio in Q2 2014.
  • DAFNA Capital Management opened 8 new positions and closed 5 in Q2 2014.
  • DAFNA Capital Management's portfolio value fell 9.3% quarter-over-quarter to $106M.

Based on DAFNA Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.